Phase 1 Clinical Trial of Elamipretide in Intermediate Age-Related Macular Degeneration and High-Risk Drusen: ReCLAIM High-Risk Drusen Study

PURPOSE: To assess safety, tolerability, and feasibility of subcutaneous administration of the mitochondrial-targeted drug elamipretide in patients with intermediate age-related macular degeneration (AMD) and high-risk drusen (HRD) and to perform exploratory analyses of change in visual function. DE...

Descripción completa

Detalles Bibliográficos
Autores principales: Allingham, Michael J., Mettu, Priyatham S., Cousins, Scott W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9560633/
https://www.ncbi.nlm.nih.gov/pubmed/36246187
http://dx.doi.org/10.1016/j.xops.2021.100095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9560633/
https://www.ncbi.nlm.nih.gov/pubmed/36246187
http://dx.doi.org/10.1016/j.xops.2021.100095

Ejemplares similares